Bicycle Therapeutics (FRA:50BA) Other Long-Term Liabilities: €0.81 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:50BA Bicycle Therapeutics PLC FRA:50BA
56 GF Score
Price €3.60
GF Value €10.84
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Other Long-Term Liabilities?

Bicycle Therapeutics FRA:50BA +1.69% 56 Other Long-Term Liabilities is €0.81 Mil as of Jun. 2026. GuruFocus rates FRA:50BA with a GF Score™ of 56/100 and a GF Value™ of €10.84 (Possible Value Trap). The stock has 5 warning signs investors should review.

Bicycle Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was €0.81 Mil.

Bicycle Therapeutics's quarterly other long-term liabilities declined from Dec. 2025 (€0.88 Mil) to Mar. 2026 (€0.84 Mil) and declined from Mar. 2026 (€0.84 Mil) to Jun. 2026 (€0.81 Mil).

Bicycle Therapeutics's annual other long-term liabilities declined from Dec. 2023 (€4.20 Mil) to Dec. 2024 (€1.07 Mil) and declined from Dec. 2024 (€1.07 Mil) to Dec. 2025 (€0.88 Mil).

Bicycle Therapeutics Other Long-Term Liabilities Related Terms

Bicycle Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Bicycle Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics Other Long-Term Liabilities Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 2.90 3.61 4.20 1.07 0.88

Bicycle Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 0.93 0.88 0.84 0.81
FRA:50BA
56GF Score
Bicycle Therapeutics PLC FRA:50BA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicycle Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €0.81 Mil mean?
Bicycle Therapeutics (FRA:50BA) has a Other Long-Term Liabilities of €0.81 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bicycle Therapeutics and its competitors.
Is Bicycle Therapeutics' Other Long-Term Liabilities too high?
Bicycle Therapeutics' current Other Long-Term Liabilities is €0.81 Mil. Overall, Bicycle Therapeutics has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Other Long-Term Liabilities compare to CYDY and ALXO?
Bicycle Therapeutics' Other Long-Term Liabilities of €0.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bicycle Therapeutics and its competitors. Bicycle Therapeutics's current Other Long-Term Liabilities is €0.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €10.84, compared to a current price of €3.60 — trading 66.8% below its estimated fair value. The current Other Long-Term Liabilities is €0.81 Mil. Bicycle Therapeutics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current Other Long-Term Liabilities is €0.81 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.60 is trading 66.8% below its estimated GF Value™ of €10.84. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

  • Other Long-Term Liabilities: €0.81 Mil
  • GF Value™: €10.84 vs. price of €3.60 (66.8% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA50BA:Germany
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score

Get the complete analysis for FRA:50BA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.60
Price
€10.84
GF Value